Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer
Published in: Breast Cancer 4/2017

01-07-2017 | Special Feature

Objection to postoperative radiation therapy in breast cancer with one to three lymph nodes involvements

Authors: Takashi Ishikawa, Hiroshi Kaise, Kimito Yamada, Mari Hosonaga, Takashi Chishima, Kazutaka Narui, Akimitsu Yamada, Sadatoshi Sugae, Yasushi Ichikawa, Mitsuyoshi Ota, Miyako Nozaki, Ryuji Mikami, Koichi Tokuuye

Published in: Breast Cancer | Issue 4/2017

Login to get access

Abstract

My arguments regarding postmastectomy radiotherapy (PMRT) for this case are based on the following 4 reasons: (1) high rate of local recurrence in the no PMRT group in the Early Breast Cancer Trialists’ Collaborative Group meta-analysis on which the present guideline is based, (2) stage migration by sentinel node biopsy, (3) possible adverse events of radiotherapy, and (4) problems on extrapolation of data from western countries.
Literature
1.
2.
Kunkler IH, Canney P, van Tienhoven G, Russell NS. MRC/EORTC (BIG 2-04) SUPREMO Trial Management Group. Elucidating the role of chest wall irradiation in ‘intermediate-risk’ breast cancer: the MRC/EORTC SUPREMO trial. Clin Oncol (R Coll Radiol). 2008;20(1):31–4.CrossRef
3.
McGale P, Taylor C, Correa C, Cutter D, Duane F, Ewertz M, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. EBCTCG (Early Breast Cancer Trialists’ Collaborative Group). Lancet. 2014;383(9935):2127–35.CrossRefPubMed
4.
Matsunuma R, Oguchi M, Fujikane T, Matsuura M, Sakai T, Kimura K, et al. Influence of lymphatic invasion on locoregional recurrence following mastectomy: indication for postmastectomy radiotherapy for breast cancer patients with one to three positive nodes. Int J Radiat Oncol Biol Phys. 2012;83(3):845–52. doi:10.​1016/​j.​ijrobp.​2011.​08.​029 (Epub 2011 Dec 3).CrossRefPubMed
5.
Taghian A, Jeong JH, Mamounas E, Anderson S, Bryant J, Deutsch M, et al. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials. J Clin Oncol. 2004;22(21):4247–54 (Epub 2004 Sep 27).CrossRefPubMed
6.
Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Lancet. 2012;379(9814):432–44. doi:10.​1016/​S0140-6736(11)61625-5 (Epub 2011 Dec 5).CrossRefPubMed
7.
Maaskant AJ, van de Poll-Franse LV, Voogd AC, Coebergh JW, Tutein Nolthenius-Puylaert MC, et al. Stage migration due to introduction of the sentinel node procedure: a population-based study. Breast Cancer Res Treat. 2009;113(1):173–9. doi:10.​1007/​s10549-008-9913-8 (Epub 2008 Feb 8).CrossRefPubMed
8.
McBride A, Allen P, Woodward W, Kim M, Kuerer HM, et al. Locoregional recurrence risk for patients with T1,2 breast cancer with 1–3 positive lymph nodes treated with mastectomy and systemic treatment. Int J Radiat Oncol Biol Phys. 2014;89(2):392–8. doi:10.​1016/​j.​ijrobp.​2014.​02.​013 (Epub 2014 Apr 7).CrossRefPubMed
9.
Huo D, Hou N, Jaskowiak N, Winchester DJ, Winchester DP, Yao K. Use of postmastectomy radiotherapy and survival rates for breast cancer patients with T1–T2 and one to three positive lymph nodes. Ann Surg Oncol. 2015;22(13):4295–304. doi:10.​1245/​s10434-015-4528-x (Epub 2015 Mar 28).CrossRefPubMed
10.
Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Brønnum D, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368(11):987–98. doi:10.​1056/​NEJMoa1209825.CrossRefPubMed
11.
Warren LE, Miller CL, Horick N, Skolny MN, Jammallo LS, Sadek BT, et al. The impact of radiation therapy on the risk of lymphedema after treatment for breast cancer: a prospective cohort study. Int J Radiat Oncol Biol Phys. 2014;88(3):565–71.CrossRefPubMedPubMedCentral
12.
Guidelines for diagnosis and treatment of carcinoma of the stomach. 2010 edited by the Japanese Gastric Cancer Society. Kanehara Shuppan.
13.
14.
Poortmans PM, Collette S, Kirkove C, Van Limbergen E, Budach V, Struikmans H, et al. EORTC radiation oncology and breast cancer groups. Internal mammary and medial supraclavicular irradiation in breast cancer. N Engl J Med. 2015;373:317–27.CrossRefPubMed
15.
Whelan TJ, Olivotto IA, Parulekar WR, Ackerman I, Chua BH, Nabid A, et al. MA.20 Study Investigators. Regional Nodal Irradiation in Early-Stage Breast Cancer. N Engl J Med. 2015;373(4):307–16.CrossRefPubMedPubMedCentral
Metadata
Title
Objection to postoperative radiation therapy in breast cancer with one to three lymph nodes involvements
Authors
Takashi Ishikawa
Hiroshi Kaise
Kimito Yamada
Mari Hosonaga
Takashi Chishima
Kazutaka Narui
Akimitsu Yamada
Sadatoshi Sugae
Yasushi Ichikawa
Mitsuyoshi Ota
Miyako Nozaki
Ryuji Mikami
Koichi Tokuuye
Publication date
01-07-2017
Publisher
Springer Japan
Published in
Breast Cancer / Issue 4/2017
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-016-0749-5

Other articles of this Issue 4/2017

Breast Cancer 4/2017 Go to the issue

Original Article

Body mass index and menopausal disorders during menopause affect vasomotor symptoms of postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes

Erratum

Erratum to: Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer

Special Feature

Post-mastectomy radiation therapy in breast cancer with 1–3 involved lymph nodes: the Pros

Original Article

Long non-coding RNA TUG1 promotes cell proliferation and metastasis in human breast cancer

Original Article

Atypical femoral fracture after receiving antiresorptive drugs in breast cancer patients with bone metastasis

Original Article

Complete remission in metastatic breast cancer: expecting the unexpected—results of a cross-sectional study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits